Podcasts

Selling in a Competitive Ultra-Orphan Disease Market
Bill Zabel, Vice President, U.S. Sales, Talecris Biotherapeutics tells us about leveraging distribution to maximize outcomes by using patient advocates to raise disease awareness and managed care strategies to gain buy-in and support. (Length 46:12)
Published: 10.01.2010 | Listen | Download Podcast *
21st Century Medicine: The Promise and the Problems
Dr. Andy von Eschenbach, Senior Director for Strategic Initiatives, Center for Health Transformation, discusses the implications for the health care delivery system when medicine is personalized, predictive, preemptive and participatory, and the benefits of developing the structural and functional changes required across the spectrum of discovery–development–delivery to bring the fruits of R&D to patients. (Length 55.55)
Published: 10.01.2010 | Listen | Download Podcast *
Patient Centered Health Management/REMS 2.0
David Sirois, DMD, PhD, President of the Board of Directors, International Pemphigus & Pemphigoid Foundation (IPPF) discusses outcomes of a model for improving Ultra-Orphan illness through an individualized Health Management Program. (Length 27.34)
Published: 10.01.2010 | Listen | Download Podcast *
New Complexities in Pricing Orphan and Ultra-Orphan Drugs
Doug Paul, Partner, MME LLC elaborates how increased competition and changes in markets are pushing ultra-orphan drug prices downward. (Length 41:36)
Published: 10.01.2010 | Listen | Download Podcast *
Patient Panel: the impact of living with a rare disorder
Moderated by Diane Edquist Dorman, a patient panel discusses the types of support that are meaningful to patients and caregivers living with a rare disorder. (Length: 56.38)
Published: 10.01.2010 | Listen | Download Podcast *
Panel: Getting drugs to market faster, cheaper, and safer
A panel of Jayson Slotnik, Attorney, Foley Hoag, LLP, Washington, D.C.; Peter Saltonstall, President & CEO, National Organization for Rare Disorders and Michael McCaughan, Editor-in-Chief, Prevision Policy, LLC; moderated by Wayne Oliver, Vice President and Georgia Project leader, The Center for Health Transformation examines How Health Care Reform helps or hurts getting drugs to market faster, cheaper, and safer, and what should companies be doing to be prepared. (Length 53.20)
Published: 10.01.2010 | Listen | Download Podcast *
Big or Small: Drug Development Post-Health Care Reform
Michael McCaughan, Editor in Chief, Prevision Policy, LLC, explains what Health Care Reform does (and doesn’t) change about drug development, how FDA regulation is evolving at the same time and where we are headed next. (Length 44.46)
Published: 10.01.2010 | Listen | Download Podcast *
Pfizer, Inc.
Ed Mascioli, M.D., Vice President, BioTherapeutics R&D, Orphan and Genetic Diseases, Pfizer, Inc. reviews Pfizer’s past experience in discovering, developing, and commercializing therapies for rare diseases and how Pfizer is restructuring to position itself to compete in this marketplace. (Length 22.35)
Published: 10.01.2010 | Listen | Download Podcast *
Getting the Product to the Patient – Who is taking care of your customer?
Craig Kephart, President & CEO, Centric Health Resources, Inc. articulates ways to get your patient strategy aligned with patient needs, incentives and channel partners.
Published: 10.01.2010 | Listen | Download Podcast *
2010 Ultra Orphan Conference Opening Remarks
Craig Kephart, President & CEO, Centric Health Resources, Inc. kicks off the event. (Length 15:05)
Published: 10.01.2010 | Listen | Download Podcast *
Manufacturer Viewpoints and Initiatives
Roger Garceau, M.D., FAAP, Senior Vice President, R&D and Chief Medical Officer, NPS Pharmaceuticals, Inc. explains why and how investing in the orphan drug marketplace makes sense with predictions on how innovation will take place in the rare disease market going forward. (Length 29.55)
Published: 10.01.2010 | Listen | Download Podcast *
The Effect of REMS on Product Commercialization
David A. Galardi, Pharm.D., Commercialization, Apogenics Inc. gives a REMS overview with emphasis on commercialization and the fallacy of standardization. (Length 48.21)
Published: 10.01.2010 | Listen | Download Podcast *
Reimbursement Implications and Strategies for Distribution Model Options
Dean Erhardt, Principal, D2Pharma Consulting, LLC presents reimbursement care updates and trends related to orphan drugs and strategies for exclusive, limited, and open distribution models. (Length 22.22)
Published: 10.01.2010 | Listen | Download Podcast *
Patient Centered Health Management
Doug Carlson, VP Health Management & Quality, Centric Health Resources, Inc. presents new models for delivering health management including HealthConnect: Centric’s new platform. (Length 15.46)
Published: 10.01.2010 | Listen | Download Podcast *
Data is Where You Mine It
Data. It's key to maximizing sales of an ultra-orphan drug. Listen to Craig Kepkart, President and CEO of Centric Health Resources, explain why data is so important, changes in the industry because of this fact and how patients' lives are affected. (Length 8:30)
Published: 10.23.2009 | Listen | Download Podcast *
Countdown to launch: T-minus … hold on a second.
Is your risk strategy really ready for the FDA? Is your reimbursement plan really ready to synch with providers? Does your pricing really reflect your channel costs? Listen to our podcast and learn how Centric works to reinvigorate your reimbursement strategy, set the right price up front and how all this will lead you with confidence right to the launchpad.
Published: 09.10.2009 | Listen | Download Podcast *
Patients First. Last. Always. Repeat.
Centric CEO, Craig Kephart, talks about best practices for ultra-orphan drugs launch, distribution and management.
Published: 08.04.2009 | Listen | Download Podcast *
Dennis Matheis - 2008 Centric Conference
Hear about reimbursement trends and what these trends mean for high-cost specialty drugs. (Length 5:04)
Published: 08.04.2009 | Listen | Download Podcast *

* To download a podcast PC users right click on the download link and choose 'Save target as...'. Mac users control click and do the same.